(Q45053701)

9 December 2017

title

Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer (English)

1 reference

9 December 2017

1 reference

1 reference

2

Olav Dahl

1 reference

9 December 2017

Halfdan Sørbye

1

1 reference

9 December 2017

publication date

1 January 2004

1 reference

9 December 2017

1 reference

9 December 2017

volume

43

1 reference

9 December 2017

issue

5

1 reference

9 December 2017

page(s)

495-498

1 reference

CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA).

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02841860410032380

Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410032380

Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410032380

A systematic overview of chemotherapy effects in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410032380

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410032380

Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410032380

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410032380

Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410032380

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410032380

The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860410032380

10.1080/02841860410032380

21 January 2018

Identifiers

DOI

1 reference

9 December 2017

1 reference